[68Ga]Ga-DOTATATE PET/CT在野生型KIT/PDGFRA胃肠道间质瘤中的作用
本研究对12例野生型胃肠道间质瘤(wtGIST)患者行[68Ga]Ga-DOTATATE PET/CT,并对54份肿瘤样本行SSTR2免疫组化。结果显示75%病例肝转移摄取低于背景肝,SSTR2并非wtGIST的诊断或治疗靶点,但该显像有助于鉴别副神经节瘤。
要点
- wtGIST中SSTR2表达不足以作为诊断或治疗靶点。
- [68Ga]Ga-DOTATATE PET/CT在多数wtGIST肝转移中呈阴性。
- 该显像可鉴别wtGIST患者合并的副神经节瘤。
核心结论
- SSTR2不是wtGIST的诊断或治疗靶点。
- [68Ga]Ga-DOTATATE PET/CT可能有助于鉴别wtGIST与副神经节瘤等其他原发肿瘤。
研究设计与样本
- 对11例确诊或转移性wtGIST及1例疑似转移性wtGIST患者行[68Ga]Ga-DOTATATE PET/CT。
- 对54份肿瘤样本行SSTR2免疫组化,其中8份来自参与显像研究的12例患者中的8例(66.6%),46份来自未参与显像研究的个体。
主要发现
- 9/12例(75%)[68Ga]Ga-DOTATATE PET/CT为阴性,肝转移摄取低于背景肝。
- 2例(16.6%)wtGIST显示生长抑素示踪剂不均匀摄取。
- 1例同时性副神经节瘤和1例异时性副神经节瘤显示强烈示踪剂摄取。
临床怎么用
- wtGIST患者不应基于SSTR2表达选择[177Lu]Lu-DOTATATE治疗。
- [68Ga]Ga-DOTATATE PET/CT可用于鉴别wtGIST患者是否合并副神经节瘤。
局限性
- 样本量小(12例显像患者),结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: [68 Ga]Ga-DOTATATE PET/CT is now recognised as the most sensitive functional imaging modality for the diagnosis of well-differentiated neuroendocrine tumours (NET) and can inform treatment with peptide receptor radionuclide therapy with [177Lu]Lu-DOTATATE. However, somatostatin receptor (SSTR) expression is not unique to NET, and therefore, [68 Ga]Ga-DOTATATE PET/CT may have oncological application in other tumours. Molecular profiling of gastrointestinal stromal tumours that lack activating somatic mutations in KIT or PDGFRA or so-called 'wild-type' GIST (wtGIST) has demonstrated that wtGIST and NET have overlapping molecular features and has encouraged exploration of shared therapeutic targets, due to a lack of effective therapies currently available for metastatic wtGIST. AIMS: To investigate (i) the diagnostic role of [68 Ga]Ga-DOTATATE PET/CT; and, (ii) to investigate the potential of this imaging modality to guide treatment with [177Lu]Lu-DOTATATE in patients with wtGIST. METHODS: [68 Ga]Ga-DOTATATE PET/CT was performed on 11 patients with confirmed or metastatic wtGIST and one patient with a history of wtGIST and a mediastinal mass suspicious for metastatic wtGIST, who was subsequently diagnosed with a metachronous mediastinal paraganglioma. Tumour expression of somatostatin receptor subtype 2 (SSTR2) using immunohistochemistry was performed on 54 tumour samples including samples from 8/12 (66.6%) patients who took part in the imaging study and 46 tumour samples from individuals not included in the imaging study. RESULTS: [68 Ga]Ga-DOTATATE PET/CT imaging was negative, demonstrating that liver metastases had lower uptake than background liver for nine cases (9/12 cases, 75%) and heterogeneous uptake of somatostatin tracer was noted for two cases (16.6%) of wtGIST. However, [68 Ga]Ga-DOTATATE PET/CT demonstrated intense tracer uptake in a synchronous paraganglioma in one case and a metachronous paraganglioma in another case with wtGIST. CONCLUSIONS: Our data suggest that SSTR2 is not a diagnostic or therapeutic target in wtGIST. [68 Ga]Ga-DOTATATE PET/CT may have specific diagnostic utility in differentiating wtGIST from other primary tumours such as paraganglioma in patients with sporadic and hereditary forms of wtGIST.
引用
- Aloj L, Giger O, Mendichovszky IA, et al. The role of [68 Ga]Ga-DOTATATE PET/CT in wild-type KIT/PDGFRA gastrointestinal stromal tumours (GIST). EJNMMI Res. 2021. PMID: 33443647. doi:10.1186/s13550-021-00747-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。